Back

Empagliflozin inhibits increased Na influx in HFpEF cardiomyocytes and reduces arrhythmic activity in human atrial trabeculae

26 August 2022 (13:15 - 13:30)
Organised by:
Congress Presentation Part of: Young Investigator Awards Session in Basic Science Heart Failure ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Maximilian Trum

University Hospital Regensburg, Regensburg (Germany)

3 More presentations in this session

Presentation thumbnail
Aberrant interaction between TEAD1 and Lamin A/C causes cardiomyopathy
Doctor S. Yamada (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Atrial-specific reduction of Kir2.1 channel pore diameter in addition to loss of inward-going rectification underlies inducible atrial fibrillation in a mouse model of short QT syndrome type 3
Miss A. Moreno Manuel (Rehovot, IL)
Abstract Slides Video
Presentation thumbnail
Single-cell transcriptomics reveals an angiogenic cell population for therapeutic angiogenesis in adipose tissue
Doctor O. Inoue (Kanazawa, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Awards Session in Basic Science

The Event

Event poster

ESC Congress 2022

26 August 2022 13:15 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors inhibit the late sodium current.
26 August 2022
thumbnail
Congress Presentation
Empagliflozin reduces extracellular volume and myocardial sodium content in patients with heart failure and preserved ejection fraction and correlates with reverse cardiac remodeling (EMPAG CMR-HF)
29 August 2025
thumbnail
Congress Session
Basic and Translational Late-Breaking Science session
27 August 2023
thumbnail
Congress Presentation
SGLT2 blockers in AF: the best AAD ever?
3 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources